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been considered important in characterizing the cell-
surface receptors present in a particular cell or tissue.
A central assumption has been that antagonist affinity is
constant for a given receptor–antagonist interaction,
regardless of the agonist used to stimulate that receptor
or the downstream response that is measured. As a
consequence, changes in antagonist affinity values have
been taken as initial evidence for the presence of novel
receptor subtypes. Emerging evidence suggests, how-
ever, that receptors can possess multiple binding sites
and the same receptor can show different antagonist
affinity measurements under distinct experimental con-
ditions. Here, we discuss several mechanisms by which
antagonists have different affinities for the same recep-
tor as a consequence of allosterism, coupling to different
G proteins, multiple (but non-interacting) receptor sites,
and signal-pathway-dependent pharmacology (where
the pharmacology observed varies depending on the
signalling pathway measured).
Introduction
The measurement of antagonist affinity has traditionally
been an important feature of the characterization of cell
surface receptors [1–5] and has been used to identify novel
receptor subtypes [1,3,6,7]. A central assumption of this
approach is that antagonist affinity is constant for a given
receptor–antagonist interaction, regardless of the agonist
used to stimulate that receptor or the downstream res-
ponse that is measured [6]. However, there is emerging
evidence that receptors can have multiple binding sites
and that the same receptor can exhibit different antagonist
affinity measurements under different experimental con-
ditions [8–13]. It might, therefore, be timely to ‘rethink’
this basic concept in pharmacology.
Classical analysis of functional agonist–antagonist
interactions
Analysis of logarithmic concentration–response curves has
long been used to evaluate the nature of the competitive
interactions between agonists and antagonists from func-
tional measurements and particularly so in the case ofCorresponding author: Hill, S.J. (stephen.hill@nottingham.ac.uk).
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standard approach is the construction of full agonist con-
centration–response curves in the absence and presence of
fixed concentrations of antagonist. The extent of the parallel
rightward shift in the position of the agonist concentration–
response curve is then used to calculate the antagonist
affinity directly (assuming competitive antagonism) or (if
various antagonist concentrations have been used) to con-
struct a Schild plot, which will have a slope of one if the
interaction is competitive (Figure 1).
Theprincipal assumptionsmade in these calculationsare
(i) that there is only one binding site; (ii) that the agonist and
the antagonist are competing at this same site; and (iii) that,
for a given level of response, the agonist occupancy of the
receptors will be identical in the presence and absence of
antagonist [1]. This latter assumption is required to take
into account the two fundamental properties of an agonist:
namely, affinity and efficacy, which contribute to the final
measured response [14,15]. Provided that the agonist–
antagonist interactionwith the receptor is competitive, then
the ratio of agonist concentrations required togive the same-
sized functional response in the presence and absence of
antagonist is equal to 1 + BKb, whereB is the concentration
of antagonist and Kb is the antagonist affinity constant [1]
(Figure 1). For a given receptor, the Kb value derived from
this relationship should be independent of the agonist used
to stimulate the receptor and the level in the receptor
signalling cascade at which responses are measured. For
example, in the case of the histamine H2 receptor, affinity
constants for the H2 antagonist famotidine are the same
whether histamine, amthamine orNa-methylhistamine are
used as H2 receptor agonists [16] (Figure 1).
Allosteric antagonism
It has been accepted for some time that some GPCRs (most
notably muscarinic, adenosine and CCR5 receptors) have
more than one binding site [17–21]. Endogenous ligands
bind to and activate the orthosteric site, whereas others,
known as ‘allosteric ligands’, bind to a separate site or sites
on the same receptor. As a consequence, both the orthos-
teric and allosteric sites can be occupied by ligands at the
same time.
Ligandsbinding to theallosteric site canalter thebinding
of ligands to the orthosteric site and have traditionally been
considered not to induce a receptor response on their own..2007.06.011
Figure 1. Antagonism of histamine H2 receptor responses. (a) Antagonism of histamine-stimulated CRE (cAMP response element) gene transcription, mediated through the
H2 receptor, by increasing concentrations of the H2 antagonist famotidine in CHO cells expressing the human H2 receptor. Gene transcription was measured by using a
secreted placental alkaline phosphatase (SPAP) reporter gene. (b) Schild plots of the famotidine antagonism of H2 responses stimulated by histamine, N
a-methylhistamine
and amthamine. The x-axis intercept gives the log Kb value. Data are from Ref. [16] and J.G.B. (unpublished observations).
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site and increases the binding affinity of an orthosteric
ligand, causing the concentration–response curve of an
orthosteric agonist to move leftward to lower agonist con-
centrations. A negative allosteric regulator decreases the
binding of the orthosteric ligand such that either the orthos-
teric agonist concentration–response curve will be shifted
to higher agonist concentrations (i.e. rightward) or the
maximum response will be decreased (depending on the
signalling efficiency of the orthosteric site). In this situation,
the allosteric ligand is effectively acting as an allosteric
antagonist.
The nature of the antagonism produced by an allosteric
antagonist is therefore very different from the classic com-
petitive antagonism described earlier (where the agonist
and antagonist compete for binding to the same orthosteric
site),whichhas several important consequences.Whenall of
the allosteric sites are occupied, the orthosteric agonist
concentration–response curve cannot be shifted any further
to the right and will reach a limiting value. This can lead to
nonlinear Schild plots and to incomplete displacement of
radioligands from their specific binding sites [10].
The effect of the allosteric antagonist can varymarkedly
depending on the agonist under study [10]. For example,
the M2 muscarinic allosteric ligand eburnamonine
enhances the agonist affinity of pilocarpine at the orthos-
teric site, has no net effect on the binding affinity ofwww.sciencedirect.comarecaidine propargyl ester, but reduces the agonist affinity
of arecoline [10,22]. In addition, the magnitude of the shift
of agonist affinities varies not only between agonists but
also with different allosteric ligands, even at the same
allosteric site [10]. Thus, each ‘allosterically occupied’ form
of the receptor can be considered to represent a confor-
mationally altered receptor that will have its own unique
set of ligand affinities and efficacies [10,21,22].
Different G-protein-coupled states of GPCRs
Increasing evidence indicates that GPCRs can couple to
more than one G protein, raising the possibility that
different agonists can direct signalling from the receptor
to specific signalling cascades as a consequence of their
relative affinities for different G-protein-coupled states of
the same receptor [13,23,24]. This possibility was first
realized for the 5-HT2C receptor, which in Chinese hamster
ovary (CHO) cells can couple to two different signalling
pathways (phosphoinositide hydrolysis and arachidonic
acid release) with a different rank order of agonist effica-
cies [23]. It is equally possible, however, that antagonists
might differ in their affinity for these G-protein-specific
states of the receptor, which will be manifest in both
agonist and signalling-pathway-dependent pharmacology.
When expressed in CHO cells, the human adenosine A1
receptor couples to both Gi and Gs proteins [24,25]. When
antagonist affinity measurements were made at both the
376 Opinion TRENDS in Pharmacological Sciences Vol.28 No.8Gi- and Gs-coupled forms of the A1 receptor, however, the
antagonist affinities were found to be constant, regardless
of the signalling cascade that was monitored (Gi or Gs) or
the level at which the signalling cascade was evaluated
(cAMP or CRE-mediated gene expression) [26] (Figure 2).
Thus, in this study the fundamental pharmacological con-
cept that antagonist affinities are indeed constant seems to
hold true for the A1 receptor.
This concept might not, however, apply to all GPCRs
and GPCR–G-protein complexes; indeed, studies of large
libraries of ligands and multiple signalling pathways
might be required to confirm or to refute it. Likewise,
antagonist affinity can vary for the monomeric GPCR as
compared with a dimeric or multimeric complex. Similarly,
if a complex is held in a scaffold (whether or not this
scaffold signals to different G proteins), then the antagon-
ist affinity might vary depending on the make-up of the
specific complex or scaffold in each cell type.
Because it is becoming increasing clear that specific
GPCR–G-protein signalling complexes seem to be compart-
mentalized in microdomains within the same cellFigure 2. 50-N-ethylcarboxamidoadenosine (NECA)-induced gene transcription mediate
adenosine A1 receptor to CRE-mediated gene transcription in CHO cells expressing the h
A. 6  CRE–SPAP signifies a SPAP reporter gene containing six CRE elements. (b) Conce
CRE gene transcription in the presence and absence of increasing concentrations of DP
www.sciencedirect.com[27,28], single-molecule approaches might be required to
determine antagonist affinities in specific microdomains of
single living cells [29,30].
Non-interacting conformations of the same GPCR
The large number of ligands available for the
b-adrenoceptor family of GPCRs has enabled detailed
studies to be performed on these receptors. For example,
there is now strong evidence that the human b1 adreno-
ceptor has at least two ligand-binding sites, each with
unique pharmacological properties [31–33]. These sites
are distinguishable by the ability of b-antagonists to show
markedly different antagonist affinities dependent on the
agonist being used to stimulate the b1 adrenoceptor [31].
Initial evidence for multiple binding sites on the b1
adrenoceptor came from detailed studies with CGP
12177. This compound is a high-affinity neutral antagonist
of the classical ‘catecholamine’-binding site of the b1 adre-
noceptor; however, at higher concentrations it produces an
agonist response that is relatively resistant to antagonism
by other classical b-antagonists [34–36]. The uniqued by the human A1 adenosine receptor. (a) Gi and Gs signalling pathways from the
uman A1-receptor. Abbreviations: CREB, CRE-binding protein; PKA, protein kinase
ntration–response curves for the effect of the agonist NECA on forskolin-stimulated
CPX. Data are from Ref. [26].
Opinion TRENDS in Pharmacological Sciences Vol.28 No.8 377pharmacological properties of the agonist actions of CGP
12177 in producing cardiostimulant effects in the heart
first led to the suggestion that a novel b4 adrenoceptor was
responsible for these effects [37]. However, the loss of this
‘b4’ activity in b1 adrenoceptor knockoutmice, coupled with
the demonstration of ‘b4’ pharmacology in cells transfected
with only the b1 adrenoceptor, led to the acceptance that
the b1 adrenoceptor has an obligatory role in the expres-
sion of this unexpected pharmacological profile [35,38].
Several studies have now examined in detail the ability
of different ligands to interact with the high-affinity ‘cat-
echolamine site’ and the low-affinity ‘CGP 12177 site’
[8,11,35,36]. Classical catecholamines such as isoprenaline
and adrenaline act as agonists of the catecholamine site,
whereas CGP 12177, LY 362884 and carvedilol have ago-
nist actions at the secondary CGP 12177 site [8,11,35,Figure 3. Differential affinities of antagonists for the ‘catecholamine’ and ‘CGP 12177’ si
concentrations of the selective b1 adrenoceptor antagonist CGP 20712A (CGPA) on is
expression. Note that the blue data points and line in (a) and (b) represent the same conc
absence and presence of fixed concentrations of cimaterol. (d) Correlation between
antagonists with the agonist isoprenaline (x axis) and log Kd determined with the same
agonist (y axis). Data are from Refs [8,11].
www.sciencedirect.com36,39]. In addition, some compounds (e.g. alprenolol and
pindolol) have agonist actions at both sites [8].
The agonist dependence of the antagonist affinity
estimates is perhaps best illustrated by a correlation plot
of the values obtained for a range of different antagonist
affinities when several different ligands were used as
agonists [8,11] (Figure 3). Although all antagonists have
low affinity for the CGP 12177 site, the rank order of
affinities varies between the two sites; for example, some
compounds (e.g. atenolol) differ by up to 1000-fold in their
affinities for the two sites, whereas others (e.g. ICI 118551)
differ by only a factor of 10 [11]. Schild analysis of the
ability of the b1 adrenoceptor antagonist CGP 20712A to
antagonise the responses at both sites indicated that both
interactions are perfectly described by a competitive inter-
action yielding a Schild slope of 1 [8] (Figure 3a,b). Thistes of the human b1 adrenoceptor expressed in CHO cells. (a,b) Effect of increasing
oprenaline-stimulated (a) and CGP-12177-stimulated (b) CRE-mediated luciferase
entration of CGP 20712A (300 nM). (c) CRE–luciferase response to CGP 12177 in the
the logarithm of the antagonist dissociation constant (log Kd) obtained for 12
12 antagonists but with adrenaline, noradrenaline, cimaterol or CGP 12177 as the
378 Opinion TRENDS in Pharmacological Sciences Vol.28 No.8finding strongly suggests that the two sites are completely
separate and non-interacting. Furthermore, because CGP
12177 is a high-affinity antagonist of the catecholamine
site (site 1), binding of CGP 12177 to the two sites of the
receptor can be observed in a single experiment.
Figure 3c shows that low concentrations of CGP 12177
inhibit cimaterol (a site-1 agonist), whereas higher con-
centrations of CGP 12177 stimulate an agonist response
(through site 2). These effects cannot simply be explained
by an allosteric regulation by CGP 12177 of the orthosteric
binding site [8,11,34,35]. Also plotted in Figure 3 is the
correlation of the antagonist affinity (log Kd) of 12
antagonists, determined in the presence of different ago-
nists (Figure 3d). The log Kd value of the antagonists is the
same whether isoprenaline, adrenaline or noradrenaline is
used as the agonist (thus, the points are indistinguishable).
The Kd values obtained for the same 12 antagonists when
CGP 12177 is used as the agonist are clearly very different,
and the rank order (seen as the pattern of scatter) does not
parallel that of the catecholamines. Lastly, although the
antagonist affinities measured when cimaterol is the ago-
nist are in the same rank order, the values obtained are
consistently higher than those obtained when the catechol-
amines are present. This observation raises the possibility
that there might be more than two ‘sites’ on the b1
adrenoceptor, or at least more than one conformation of
the catecholamine site.
The data obtained with the human b1 adrenoceptor
firmly establish the concept that theremight be additional
ligand-binding sites on GPCRs that are separate from the
classical orthosteric site and that can stimulate functional
responses. These sites do not necessarily need to interact
cooperatively and they might provide an alternative
means by which cell signalling can be initiated with a
completely different pharmacological profile and possibly
by a completely different set of ligands to those of the
orthosteric site. Furthermore, the data obtained with the
b1 adrenoceptor also beg the question of how widespread
this phenomenon is. Possibly, we have not found other
agonist sites on other GPCRs because we have not looked
for them or because our high-throughput screening
strategies are too focused on the traditional view of the
orthosteric site.
A detailed study of the human b3 adrenoceptor set out
to test precisely this possibility. Early suggestions for
multiple states of the human b3 adrenoceptor had been
put forward to explain the apparently opposite relative
potencies of b3 agonists obtained when evaluated by
cAMP measurements in intact cells and when meas-
ured by radioligand binding studies in membrane prep-
arations [40]. The differences in antagonist affinity
observed at the b3 adrenoceptor were not as pronounced
as those at the b1 adrenoceptor; however, some agonists
were clearly inhibited more potently by antagonists than
were other ligands [41]. Furthermore, ZD 7114 was
shown to be able to activate two conformations or sites
of the b3 adrenoceptor (analogous to alprenolol and pin-
dolol at the b1 adrenoceptor) and alprenolol was found to
be a neutral antagonist of one site while activating a
second site (similar to CGP 12177 at the b1 adrenoceptor)
[41].www.sciencedirect.comSignalling-pathway-dependent pharmacology
As their name suggests, the main signalling pathways by
which GPCRs have normally been thought to function is by
activation of heterotrimeric G proteins. Recent studies,
however, have provided evidence for G-protein-indepen-
dent signalling by the b2 adrenoceptor, vasopressin V2,
parathyroid hormone and angiotensin AT1 receptors [9,42–
48]. The potential for GPCRs to form complexes with
signalling proteins other than G proteins also raises the
possibility that agonists and antagonists can discriminate
between these complexes in terms of both binding affinity
and efficacy. Thus, each downstream signalling pathway
measured in a particular cell might have its own unique
pharmacology depending on the pathway stimulated by
each unique ligand–receptor conformation or complex
involved.
Some insight into the potential for the human b2
adrenoceptor to exist in different conformations (each with
its own unique pharmacology) and to couple to distinct
signalling pathways has been provided by detailed studies
of the agonist and inverse agonist properties of propranolol
on activation of the ERK1/2 mitogen-activated protein
(MAP) kinase pathway and cAMP accumulation in CHO
and human embryonic kidney 293 (HEK293) cells [9,43,49]
(Figure 4). In the case of cAMP accumulation in CHO or
HEK293 cells expressing the human b2 adrenoceptor, pro-
pranolol shows clear inverse agonist properties [9,43,49].
When ERK1/2 activation is measured in the same cells,
however, propranolol behaves as a partial agonist. It also
seems that stimulation of ERK1/2 phosphorylation by
propranolol is independent of Gi or Gs protein activation
[9,43]. Furthermore, it has been shown in HEK293 cells
that ERK1/2 stimulation involves an interaction with b-
arrestins [43]. These data suggest that ligand-specific
conformations of the b2 adrenoceptor do indeed exist that
can differentially activate distinct signalling pathways
with very different pharmacologies. A similar observation
has also been made for the murine b3 adrenoceptor, for
which SR59230A is an antagonist of CL316243-mediated
increases in cAMP accumulation in adipocytes, but is an
agonist with greater efficacy than CL316243 for extracellu-
lar acidification in the same cells [50].
It is therefore possible that antagonists might differ in
their affinity for different GPCR–signalling protein com-
plexes (e.g. Gs- and b-arrestin-coupled forms of the b2
adrenoceptor) and show agonist- and signalling-path-
way-dependent affinities. In this respect, it is interesting
that the affinity constants for different b2 adrenoceptor
antagonists obtained in gene transcription studies in cells
expressing the b2 adrenoceptor were found to differ by a
factor of 10 depending on the competing agonist [51]. The
exact mechanisms underlying this observation, however,
remain to be established.
Other receptors with different ‘pharmacological’
antagonist affinities
Comparison of the antagonist affinities estimated from
radioligand binding studies and those estimated from
functional studies with the same ligands shows that there
are major discrepancies in the affinities obtained at the b1
adrenoceptor. For example, binding of 3H-labelled CGP
Figure 4. Dual efficacy of propranolol on b2-adrenoceptor-mediated responses in CHO cells expressing the human b2 adrenoceptor. (a) Inverse agonist effect of propranolol
on [3H]cAMP accumulation. 6  CRE–SPAP signifies a SPAP reporter gene containing six CRE elements. (b) Agonist effects of isoprenaline and propranolol on levels of
phosphorylated ERK1/2 monitored by an ELISA assay. (c) Agonist effect of propranolol on CRE-mediated gene transcription. Data are from Ref. [9].
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when propranolol antagonises the CGP 12177 agonist
response in functionalassays, however, theaffinityobtained
is 363 nM [11,52]. This discrepancy arises because the low
concentration of 3H-labelled CGP 12177 used in the binding
assay ismeasuring site-1 binding (there is not sufficient 3H-
labelled CGP 12177 present to occupy site 2), whereas the
CGP 12177 agonist response is occurring at site 2 and
therefore propranolol affinity at site 2 is being measured.
Antagonist affinities measured in functional assays with
site-1 agonists correlate well with the binding studies.
Comparing similar data from other receptors is a means
by which insight might be gained into how widespread the
presence of multiple binding sites might be in GPCRs.
For example, the a1L adrenoceptor might represent an
alternative conformation of the a1A adrenoceptor [53–55].
The a1L adrenoceptor in functional studies in native tissues
has a unique pharmacological profile that is characterized
by lower affinities for prazosin, WB 4101, 5-methylurapidil
and S-niguldipine than would be predicted from studies of
ligand binding to the a1A adrenoceptor [53,56,57]. Other
ligands such as tamsulosin and indoramin, however, yield
identical binding affinities between the two assays. Expres-
sion of the clonedhumana1A adrenoceptor inCHOcells, and
comparison of antagonist affinities between ligand bindingwww.sciencedirect.comstudies and functional noradrenaline-stimulated inositol
phosphate responses, has yielded a1A adrenoceptor (bind-
ing) and a1L adrenoceptor (functional) pharmacologies
[53,54]. It ispossible, therefore, that thepresenceofmultiple
binding sites on thea1A adrenoceptor (analogous to those on
the human b1 and b3 adrenoceptor) or signalling-pathway-
dependent a1A adrenoceptor conformations might explain
these discrepancies.
Concluding remarks
It is now clear that, for many GPCRs, antagonist affinities
can no longer be assumed to be always constant for a
particular receptor. Antagonist affinities can vary depend-
ing on the agonist that they are counteracting, the presence
or absence of allosteric ligands, the specific site on theGPCR
through which they exert their effect, and the specific sig-
nallingpathwayunderconsideration.The fact thatantagon-
ist drugs canhavedifferential effects at different sites on the
same receptormeans that we should no longer simply think
in terms of ‘class effects’ of receptor antagonists. This con-
cept is particularly importantwhenwe consider ‘antagonist’
drugs that can manifest different effects on specific signal-
ling cascades through a single receptorwithin the same cell.
Instead, we should explore the huge potential provided
bymultiple binding sites and divergent signalling cascades
380 Opinion TRENDS in Pharmacological Sciences Vol.28 No.8from the same GPCR, while at the same time exploiting
quantitative analytical approaches and novel screening
designs to re-evaluate how widespread these phenomena
are.
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